Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study

Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Blood (Impact Factor: 9.78). 06/2008; 111(12):5515-23. DOI: 10.1182/blood-2007-10-117150
Source: PubMed

ABSTRACT Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for late effects of cancer therapy. Five-year ALL survivors (< 21 years at diagnosis; n = 5760 eligible, 4151 participants), diagnosed from 1970 to 1986 were compared with the general population and a sibling cohort (n = 3899). Cumulative mortality of 5760 5-year survivors was 13% at 25 years from diagnosis. Recurrent ALL (n = 483) and second neoplasms (SNs; n = 89) were the major causes of death. Among 185 survivors, 199 SNs occurred, 53% in the CNS. Survivors reported more multiple chronic medical conditions (CMCs; odds ratio [OR], 2.8; 95% CI, 2.4-3.2) and severe or life-threatening CMCs (OR, 3.6; 95% CI, 3.0-4.5) than siblings. Cumulative incidence of severe CMCs, including death, 25 years from diagnosis was 21.3% (95% CI, 18.2-24.4; 23.3% [95% CI, 19.4-27.2] and 13.4% [95% CI, 8.4-18.4] for irradiated and nonirradiated survivors, respectively). Survivors reported more adverse general and mental health, functional impairment, and activity limitations compared with siblings (P < .001). Rates of marriage, college graduation, employment, and health insurance were all lower compared with sibling controls (P < .001). Long-term survivors of childhood ALL exhibit excess mortality and morbidity. Survivors who received radiation therapy as part of their treatment or had a leukemia relapse are at greatest risk for adverse outcomes.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The past 40 years have seen significant improvements in both event-free and overall survival for children with acute lymphoblastic or acute myeloid leukemia (ALL or AML respectively). Serial national and international clinical trials have optimised the use of conventional chemotherapeutic drugs and, along with improvements in supportive care that have enabled the delivery of more intensive regimens, have been responsible for the major improvements in patient outcome seen over the past few decades,. The benefits of dose intensification, however, have likely now been maximised, and over the same period, the identification of new cytotoxic drugs has been limited. As the biology of leukemogenesis has become better understood, key molecules and intracellular pathways have been identified that offer the possibility of targeting directly the leukemia cells whilst sparing normal cells. Consequently, there is now a drive to develop novel leukemia-specific or ‘targeted’ therapies. These new classes of drugs will have mechanisms of action, toxicities and therapeutic indices quite different from conventional cytotoxic drugs previously encountered, thus rendering current clinical trial methodologies inappropriate; clinical trial methods will need to be adapted to accommodate these features of these new classes of drugs. This review will address the challenges and some of the techniques for developing clinical trials for targeted therapies.
    Frontiers in Oncology 01/2014; 4:374. DOI:10.3389/fonc.2014.00374
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The results from the published studies on whether the risk of metabolic syndrome is high among hematologic malignancies survivors are conflicting. The aims of this study are to conduct a systematic search and assess the literature to determine the available evidence on the association between metabolic syndrome and hematologic malignancies. Two reviewers independently conducted a systemic search to identify the available evidence from PubMed, EMBASE, and Cochrane database from database inception to June 4, 2014. The articles were limited to human studies and published in English. A combined analysis was performed, followed by a subgroup analyses stratified by the type of hematologic malignancies, hematologic malignancies treatment modality, criteria of metabolic syndrome, and individual components of metabolic syndrome. Publication bias was assessed using the Begg and Egger's tests and visual inspection of funnel plot. All analysis was performed using Stata SE version 10.0 software package. Seven cross-sectional studies with a total of 3,550 participants were included in the analysis. Compared with the healthy control groups, the hematologic malignancies survivors were at an increased risk of metabolic syndrome, in the random-effect meta-analysis of all seven cross-sectional studies (OR 2.03; 95 % confidence interval (CI) 1.23-3.35; I (2) = 43.9 %). In the subgroup meta-analysis by cancer treatment modality, a significant positive association was observed for hematopoietic stem cell transplantation (OR 2.40; 95 % CI 1.71-3.35). However, no significant positive association was observed for other major cancer treatment modality, including chemotherapy and radiation therapy. Further subgroup analysis by individual metabolic syndrome components showed that the risk of high blood pressure among hematologic malignancies survivors (OR 1.67; 95 % CI 1.10-2.53) was found to be higher compared with central obesity (OR 1.43; 95 % CI 1.02-2.01), whereas no significant association between hematologic malignancies survivors and other individual components including high glucose levels, high triglyceride levels, and low HDL cholesterol levels was observed. Funnel plot inspection and Begg and Egger's tests showed no evidence of publication bias for combined analysis. Our meta-analysis of studies showed that hematologic malignancies survivors were at an increased risk of metabolic syndrome.
    Medical Oncology 01/2015; 32(1):422. DOI:10.1007/s12032-014-0422-9 · 2.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Obesity is a well documented problem associated with childhood acute lymphoblastic leukemia (ALL) with increasing body mass index often observed during therapy. This study aims to evaluate if weight gain, early in therapy, is predictive of obesity at the end of treatment.ProcedureIn this secondary analysis, data from 1,017 high-risk ALL patients previously treated on a Children's Oncology Group protocol (CCG study 1961) were reviewed. Logistic regression was used to examine whether change in BMI z-score at Induction or Delayed Intensification (DI) 1 were predictive of obesity at the end of therapy.ResultsThe BMI z-score at the beginning of Induction and the change in BMI z-score during Induction were both significant predictors of obesity at the end of therapy. The change in BMI z-score during cycle 1 of DI was not found to be associated with obesity.Conclusions It is well know that obesity at the beginning of therapy is predictive of obesity at the end of ALL therapy. The new, and more important, finding from this study is that even after adjusting for baseline weight, the increase in BMI z-scores during induction was an independent predictor of obesity at the end of therapy. Most researchers agree that prevention is the best form of treatment for obesity as it is difficult to reverse once it is present. This study suggests that monitoring weight trends during Induction may be useful in guiding healthcare practitioners in identifying which patients are at highest risk for obesity development so that early intervention may occur. Pediatr Blood Cancer © 2014 Wiley Periodicals, Inc.
    Pediatric Blood & Cancer 11/2014; DOI:10.1002/pbc.25316 · 2.56 Impact Factor

Full-text (2 Sources)

Available from
May 30, 2014